Skip to content

A retrospective analysis to study the Effectiveness and Safety profile of Remdesivir therapy in patients who diagnosed with COVID-19

Efficacy and Safety of Remdesivir in COVID-19: A retrospective analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/01/030433
Enrollment
1050
Registered
2021-01-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Dr Vishal Shanbhag
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adults patients diagnosed with laboratory-confirmed SARS-CoV-2 infection from March 2020 to September 2020 in Kasturba Hospital Manipal irrespective of gender will be included

Exclusion criteria

Exclusion criteria: Pediatric population

Design outcomes

Primary

MeasureTime frame
Mortality rate/death, Reversal of COVID-19/recovery, Duration of ICU or ventilation and/or Hospital stay, Negative RT-PCR, Improvement in Chest CT, Radiological parameters by CXR Brixia Score, and Lung Zone wise Brixia Score distributionTimepoint: The outcomes will be measured at baseline, at 24 hours, 48 hours, 72 hours, and 5days post administration of remdesivir

Secondary

MeasureTime frame
Safety measures such as Adverse events, Serious adverse events, Adverse drug reaction and Treatment discontinuationTimepoint: The outcomes will be measured or monitored at baseline, at 24 hours, 48 hours, 72 hours, and 5days post administration of remdesivir

Countries

India

Contacts

Public ContactDr Girish Thunga

Kasturba Medical College

vishal.shanbhag@manipal.edu9901960496

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026